PPA
CTXR icon

Parametric Portfolio Associates’s Citius Pharmaceuticals CTXR Stock Holding History

Parametric Portfolio Associates’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$24K Sell
539
-508
-49% -$20.1K ﹤0.01% 3656
2021
Q4 		$40K Sell
1,047
-2,172
-67% -$98.5K ﹤0.01% 3609
2021
Q3 		$163K Buy
3,219
+2,524
+363% +$127K ﹤0.01% 3472
2021
Q2 		$60K Buy
+695
New +$41.8K ﹤0.01% 3526

Other funds holding CTXR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

Parametric Portfolio Associates's CTXR Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its Citius Pharmaceuticals (CTXR) stake by 49% in Q1 2022, selling an estimated $20.1K and leaving 539 shares worth $24K. The position accounts for ﹤0.01% of the portfolio, ranked #3656.

Parametric Portfolio Associates first reported a position in CTXR in Q2 2021 and has held it in 4 quarters since. The position peaked at $163K in Q3 2021. 76 funds tracked by Wall St. Rank hold CTXR as of Q1 2022.

  • Parametric Portfolio Associates held 539 shares of Citius Pharmaceuticals worth $24K as of Q1 2022.
  • Parametric Portfolio Associates sold 508 Citius Pharmaceuticals shares in Q1 2022, an estimated $20.1K.
  • Citius Pharmaceuticals made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3656 holding.
  • Parametric Portfolio Associates first reported a position in Citius Pharmaceuticals in Q2 2021 and has held it in 4 quarters since.
  • Parametric Portfolio Associates's Citius Pharmaceuticals position peaked at $163K in Q3 2021.
  • 76 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.